AbbVie Axes Caribou Car-T Deal, Continuing Cascade of Punted Cancer Pacts

AbbVie has decided it can do without Caribou Biosciences. The Big Pharma is terminating its off-the-shelf CAR-T pact with the biotech, depriving Caribou of the chance to pocket up to $350 million in milestones per program.